Summaries & Associations of Study Results
TR-485 Oxymetholone
Target Organs and Levels of Evidence
NTP Technical Report Number 485
Produced from Chemtrack Database 09/19/01
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
|---|---|---|---|---|
| OXYMETHOLONE 434-07-1 |
10/30/98 | MAINTAIN A POSITIVE NITROGEN BALANCE. TO PROMOTE WEIGHT GAIN IN CACHEXIA, DEBILITATING DISEASES, SERIOUS INFECTIONS, BURNS, TRAUMA AND SURGERY. TREATMENT OF ANEMIAS. (NTP EXECUTIVE SUMMARY) | Gavage MR: 0, 3, 30, OR 150 MG/KG; FR: 0, 3, 30, OR 100 MG/KG | Battelle Columbus Laboratory |
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
| MR: EQUIVOCAL EVIDENCE | ||||
| MAY HAVE BEEN RELATED: | SKIN: FIBROMA 0/51 5/50 2/49 2/50 COMBINED 0/51 7/50 2/49 2/50 | |||
| ADRENAL GLAND MEDULLA: PHEOCHROMOCYTOMA 19/51 21/50 21/50 29/49 COMBINED 19/51 25/50 21/50 29/49 | ||||
| KIDNEY TUBULAR CELL: ADENOMA (STANDARD) 0/51 1/50 0/50 2/49 (EXTENDED) 4/51 12/50 1/50 5/49 COMBINED 4/51 13/50 1/50 6/49 | ||||
| NON-NEOPLASTIC LESIONS: | LIVER: BASOPHILIC FOCUS; CLEAR CELL FOCUS | |||
| LUNG: MINERALIZATION | ||||
| ADRENAL GLAND: CORTEX; CYTOPLASMIC VACUOLIZATION | ||||
| KIDNEY: MINERALIZATION; INCREASED SEVERITY OF NEPHROPATHY | ||||
| MAMMARY GLAND: LOBULAR HYPERPLASIA | ||||
| TESTES: DEGENERATION; MINERALIZATION | ||||
| OTHER CONSIDERATIONS: | TESTES: ADENOMA 33/51 20/50 0/50 0/49 | |||
| MONONUCLEAR CELL LEUKEMIA: 21/51 15/50 7/50 4/50 | ||||
| FR: CLEAR EVIDENCE | LIVER: ADENOMA 1/50 1/50 1/50 8/49 COMBINED 1/50 1/50 1/50 10/49 | |||
| LUNG: ADEMONA 0/50 0/50 6/50 1/49 COMBINED 0/50 0/50 7/50 1/49 | ||||
| SKIN: COMBINED 0/50 0/50 4/50 5/50 | ||||
| NON-NEOPLASTIC LESIONS: | LIVER: BASOPHILIC FOCUS; CLEAR CELL FOCUS | |||
| LUNG: MINERALIZATION | ||||
| ADRENAL GLAND: CORTEX, CYTOPLASMIC VACUOLIZATION | ||||
| KIDNEY: INCREASED SEVERITY OF NEPHROPATHY | ||||
| OVARY: DYSGENESIS, SEVERITY OF DYSGENESIS | ||||
| HEART: MYOCARDIUM; CHRONIC DEGENERATION, SEVERITY OF DEGENERATION | ||||
| OTHER CONSIDERATIONS: | UTERUS: STROMAL SARCOMA: 5/50 9/50 2/50 0/50 | |||
| MAMMARY GLAND: FIBROADEMONA 21/50 11/50 1/50 4/50 COMBINED 23/50 11/50 1/50 4/50 | ||||
| PITUITARY GLAND: ADEMONA 27/50 26/50 18/49 14/50 | ||||
| MONONUCLEAR CELL LEUKEMIA: 12/50 11/50 11/50 5/50 | ||||
Web page last updated on February 10, 2006
